Finance

Lists
Why is NVS up 3,14%?
Dive Deeper
NVS:NYSE
Novartis AG
146,88 USD
+3,14%
(+4,47) 1D
146,88 USD
0,00% (0,00)
After hours
Closed: 14-окт., 16:00:03 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVS...
Open
144,35 USD
High
147,16 USD
Low
144,17 USD
Mkt. cap
300,82 млд
Avg. vol.
2,40 млн
Volume
1,65 млн
Dividend
3,23%
Quarterly dividend
1,19 USD
Ex-dividend date
2026-ж., 10-мар.
P/E ratio
22,18
52-wk high
170,46 USD
52-wk low
121,57 USD
EPS
6,62 USD
Beta
0,39
Shares outstanding
2,03 млд
No. of employees
75 миң
Open
144,35 USD
High
147,16 USD
Low
144,17 USD
Mkt. cap
300,82 млд
Avg. vol.
2,40 млн
Volume
1,65 млн
Dividend
3,23%
Quarterly dividend
1,19 USD
Ex-dividend date
2026-ж., 10-мар.
P/E ratio
22,18
52-wk high
170,46 USD
52-wk low
121,57 USD
EPS
6,62 USD
Beta
0,39
Shares outstanding
2,03 млд
No. of employees
75 миң
News stories
From web sources and news partners
Global Arbitration Review
Global Arbitration Review
·
7 саат мурун
US biotech company enforces eye treatment award against Novartis
Quiver Quantitative
Quiver Quantitative
·
9 саат мурун
Why Novartis (NVS) Stock Is Up Today
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75,3 миң
Founded1996-ж., 7-мар.
HeadquartersБазель, Базель-Штадт, Швейцария
SectorPharmaceutical industry
Analyst ratings
Based on 7 analysts giving stock ratings to NVS in the past 3 months
Buy
Buy
3
Hold
3
Sell
1
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for NVS in the last 3 months.
Highest
Current 146,88 USD
180,25 USD (+22,72%)
Average
158,32 USD (+7,79%)
Lowest
136,00 USD (-7,41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sachin Jain
Bank of America Securities
Buy
Maintained
150,00 CHF
+2,1%
10/12/2026
Thibault Boutherin
Morgan Stanley
Buy
Maintained
156,00 USD
+6,2%
10/06/2026
Rajesh Kumar
HSBC
Hold
Upgraded
136,00 USD
-7,4%
09/10/2026
Steve Scala
TD Cowen
Hold
Maintained
180,00 USD
+22,5%
09/08/2026
Kerry Holford
Berenberg Bank
Hold
Maintained
147,00 USD
+0,1%
07/27/2026
Jasper Hellweg
Argus Research
Buy
Maintained
170,00 USD
+15,7%
07/24/2026
Unknown Analyst
Goldman Sachs
Sell
Maintained
139,00 USD
-5,4%
07/22/2026
Justin Smith
Bernstein
Hold
Initiated
-
-
03/19/2026
David Toung
Argus Research
Buy
Upgraded
180,00 USD
+22,5%
03/11/2026
Next call 13 күндөн кийин
27-окт., шейш., 18:40
Fiscal period
Q3 2026
- / 2,24 USD
Revenue / Est. (USD)
- / 14,67 млд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
14,36 млд
13,86 млд
13,52 млд
14,95 млд
Cost of goods sold
3,54 млд
3,54 млд
3,44 млд
3,68 млд
Cost of revenue
3,54 млд
3,54 млд
3,44 млд
3,68 млд
Research and development expenses
2,86 млд
2,84 млд
2,78 млд
2,74 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,30 млд
3,44 млд
3,14 млд
3,23 млд
Operating expense
6,24 млд
6,46 млд
5,96 млд
6,10 млд
Total operating expenses
9,77 млд
10,00 млд
9,40 млд
9,78 млд
Operating income
4,58 млд
3,86 млд
4,12 млд
5,18 млд
Other non operating income
-7,00 млн
-130,00 млн
4,00 млн
19,00 млн
EBT including unusual items
4,20 млд
3,22 млд
3,84 млд
4,27 млд
EBT excluding unusual items
4,29 млд
3,49 млд
3,78 млд
4,73 млд
Income tax expense
266,00 млн
814,00 млн
683,00 млн
1,01 млд
Effective tax rate
6,34%
25,30%
17,79%
23,71%
Other operating expenses
70,00 млн
190,00 млн
42,00 млн
127,00 млн
Net income
3,93 млд
2,41 млд
3,16 млд
3,26 млд
Net profit margin
27,36%
17,38%
23,34%
21,83%
Earnings per share
2,25
2,03
1,99
2,41
Interest and investment income
-
373,00 млн
-
-
Interest expense
-281,00 млн
-304,00 млн
-343,00 млн
-462,00 млн
Net interest expenses
-281,00 млн
69,00 млн
-343,00 млн
-462,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
5,78 млд
4,96 млд
5,24 млд
6,30 млд
Gain or loss from assets sale
81,00 млн
80,00 млн
-159,00 млн
-247,00 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору